Skip to content

US · CERS

Cerus Corporation

Programmatic access: InvestorsCraft Valuation API · catalog

Sector
Healthcare · Medical - Devices
Headquarters
Concord, CA 94520
Website
cerus.com

Price · as of 2025

$2.59

Market cap 457.46M

Valuation

MetricValueUpside
IC Value$0.78-70%
P/E-20.61
P/B5.02
P/S1.56
EV/EBITDA-60.97
PEG
P/TBV5.12

Valuation history

Annual price overlaid with each model's fair value. Y-axis is log scale.

Annual price and model valuations for CERS, USD per share
YearPriceAIICGraham-DoddGraham Formula
2011$3.73$14.69
2012$4.23$14.13
2013$6.11$12.09
2014$4.12$13.80
2015$5.65$13.25
2016$4.45$12.99
2017$4.87$13.66
2018$6.48$16.08
2019$5.49$13.21
2020$6.39$14.73
2021$5.22$15.54
2022$2.80$13.97
2023$2.26$12.68
2024$1.51$16.21
2025$1.69$14.83

Historic valuation ratios

Pick a category, then toggle metrics to compare.

USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Cerus Corporation

        Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.

        CEO
        Vivek K. Jayaraman
        Employees
        275
        Beta
        1.77

        Peer comparison

        Same-industry comparables, ranked by market cap.

        Scroll horizontally for additional metrics. Ticker column stays fixed.

        Peer comparison for CERS: basic info, valuation models, ratios, profitability, leverage, growth, cash flow, dividends, enterprise value, and Altman Z-score.
        Basic InfoIC ValuationCore ValuationProfitabilityLeverage & LiquidityGrowthCash FlowDividendsEnterprise ValueRisk
        TickerCompany NamePriceMarket CapValueUpsideP/EP/BP/SEV/EBITDAPEGP/TBVGross MarginOperating MarginNet MarginROEROICROADebt/EquityInterest CoverageCurrent RatioQuick RatioNet Debt/EBITDAEPS GrowthSales GrowthFCF GrowthFCF YieldOp Cash Flow RatioCash ROICDividend YieldDividend PayoutShareholder YieldEV/EBITEV/FCFEV/SalesAltman Z-Score
        CERSCerus Corporation$2.59457.46M$14.83+473%-20.615.021.56-60.975.1254.47%-4.21%-7.58%-25.97%-11.42%-7.39%1.51-1.041.731.12-13.96-25.45%14.35%0.00%2.65%0.1111.21%0.00%0.00%0.26%-38.7239.451.63-4.39
        CVRXCVRx, Inc.$2.3963.42M$12.49+423%-3.684.993.47-3.674.9985.33%-90.49%-94.10%-96.59%-342.11%-44.76%1.29-8.807.636.490.53-23.02%10.45%0.60%-20.75%-3.02-272.03%0.00%0.00%0.00%-3.35-4.213.03-6.15
        MASS908 Devices Inc.$8.88364.32M$24.71+178%11.281.533.91-4.282.0547.68%-43.03%-65.20%15.09%-48.74%11.15%0.124.243.653.33-125.47%-5.76%-20.12%-11.21%-0.70-49.77%0.00%0.00%26.76%-5.11-5.012.201.77
        NPCENeuroPace, Inc.$14.83505.61M$17.96+21%-21.4824.234.61-39.0424.2377.23%-16.34%-21.47%-158.74%-56.92%-21.44%3.72-2.195.284.25-4.08-29.03%25.13%-37.89%-2.46%-0.62-39.50%0.00%0.00%13.08%-28.82-41.534.71-2.83
        QTRXQuanterix Corporation$4.03189.84M$7.05+75%-1.880.681.45-1.29-1.241.4646.67%-79.20%-77.28%-34.25%-71.53%-25.97%0.132.841.98-0.08151.00%2.38%107.23%-39.67%-1.03-54.50%0.00%0.00%0.00%-1.10-1.510.87-1.09
        RXSTRxSight, Inc.$6.26259.14M$12.95+107%-7.751.092.24-2.18-22.931.0976.60%-35.84%-28.96%-13.99%-83.88%-12.36%0.04-1204.7510.959.580.2333.80%-3.89%-13.60%-6.41%-0.59-33.66%0.00%0.00%1.49%-1.76-4.380.632.97
        SENSSenseonics Holdings, Inc.$7.02293.39M$13.79+96%-3.413.866.68-2.923.9144.71%-193.83%-196.03%-310.68%629.54%-60.97%0.68-13.804.834.37-0.01-33.60%56.89%-3.92%-25.60%-2.43555.00%0.00%0.00%0.00%-2.67-3.035.18-9.73
        SGHTSight Sciences, Inc.$7.47406.44M$12.78+71%-4.982.992.47-4.282.9986.17%-47.95%-49.67%-50.74%-365.87%-29.77%0.64-7.2110.229.221.56-28.16%-3.13%31.59%-15.63%-2.69-295.05%0.00%0.00%0.00%-3.78-4.691.81-1.77
        SNWVSANUWAVE Health Inc.$5.8850.56M$35.67+507%15.60113.804.1810.05-21.2677.11%11.23%26.82%-212.89%64.71%35.02%14.190.791.380.970.57-105.83%34.98%-1.58%1.05%0.2225.49%0.00%0.00%2.31%39.49100.964.43-4.17
        TKNOAlpha Teknova, Inc.$6.46346.35M$13.76+113%-8.652.173.68-15.612.6333.17%-41.90%-42.59%-22.83%-21.20%-15.52%0.22-23.914.581.40-0.91-43.86%7.35%-27.54%-6.56%-1.15-12.23%0.00%0.00%11.55%-9.33-16.183.910.90

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.78 ÷ $2.59) − 1 = -69.88% (IC, example).